Complications of biological therapy for inflammatory bowel diseases
W Blonski, GR Lichtenstein - Current opinion in gastroenterology, 2006 - journals.lww.com
Current opinion in gastroenterology, 2006•journals.lww.com
The data concerning biologics' associated toxicity in patients with inflammatory bowel
disease are the most robust in the case of infliximab. These data are derived from both
prospective, randomized clinical trials and from post-marketing experience. In the case of
the remaining agents the data concerning safety in inflammatory bowel disease are limited,
as these agents were not evaluated in as many trials as infliximab; indeed, some of them
included only several patients.
disease are the most robust in the case of infliximab. These data are derived from both
prospective, randomized clinical trials and from post-marketing experience. In the case of
the remaining agents the data concerning safety in inflammatory bowel disease are limited,
as these agents were not evaluated in as many trials as infliximab; indeed, some of them
included only several patients.
Summary
The data concerning biologics' associated toxicity in patients with inflammatory bowel disease are the most robust in the case of infliximab. These data are derived from both prospective, randomized clinical trials and from post-marketing experience. In the case of the remaining agents the data concerning safety in inflammatory bowel disease are limited, as these agents were not evaluated in as many trials as infliximab; indeed, some of them included only several patients.
Lippincott Williams & Wilkins